Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Stock Rating Lowered by ValuEngine

ValuEngine downgraded shares of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) from a hold rating to a sell rating in a research note published on Monday, July 24th.

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) traded up 0.58% during midday trading on Monday, reaching $3.49. The company had a trading volume of 67,028 shares. Nymox Pharmaceutical Corporation has a 12-month low of $2.00 and a 12-month high of $5.79. The stock has a 50-day moving average price of $3.93 and a 200 day moving average price of $3.81. The company’s market capitalization is $182.76 million.

TRADEMARK VIOLATION WARNING: “Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Stock Rating Lowered by ValuEngine” was first posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.com-unik.info/2017/08/11/nymox-pharmaceutical-corporation-nasdaqnymx-lowered-to-sell-at-valuengine-updated-updated.html.

In other news, Director James George Robinson purchased 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 21st. The shares were bought at an average cost of $3.77 per share, for a total transaction of $56,550.00. Following the acquisition, the director now owns 3,008,150 shares of the company’s stock, valued at approximately $11,340,725.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders acquired 152,500 shares of company stock worth $583,370. 54.00% of the stock is currently owned by insiders.

A number of large investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers acquired a new stake in shares of Nymox Pharmaceutical Corporation during the second quarter valued at $134,000. Northern Trust Corp purchased a new position in Nymox Pharmaceutical Corporation during the second quarter valued at approximately $199,000. Teachers Advisors LLC purchased a new position in Nymox Pharmaceutical Corporation during the second quarter valued at approximately $218,000. Schwab Charles Investment Management Inc. purchased a new position in Nymox Pharmaceutical Corporation during the second quarter valued at approximately $222,000. Finally, Wedbush Securities Inc. raised its position in Nymox Pharmaceutical Corporation by 30.6% in the second quarter. Wedbush Securities Inc. now owns 234,692 shares of the biopharmaceutical company’s stock valued at $1,033,000 after buying an additional 55,000 shares during the period. 1.78% of the stock is owned by institutional investors.

About Nymox Pharmaceutical Corporation

Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.

To view ValuEngine’s full report, visit ValuEngine’s official website.

What are top analysts saying about Nymox Pharmaceutical Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Nymox Pharmaceutical Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit